LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

Search

TransMedics Group Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

73.67 -2.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

72.59

Max

75.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-98M

7.3M

Pardavimai

13M

174M

P/E

Sektoriaus vid.

17.279

49.712

Pelnas, tenkantis vienai akcijai

0.3

Pelno marža

4.206

Darbuotojai

898

EBITDA

-4.9M

28M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+59.25% upside

Dividendai

By Acuity

Kitas uždarbis

2026-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-744M

2.6B

Ankstesnė atidarymo kaina

75.86

Ankstesnė uždarymo kaina

73.67

Naujienos nuotaikos

By Acuity

50%

50%

128 / 342 reitingas Healthcare

TransMedics Group Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Apie bendrovę TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat